| Status: Recommended with restrictions | |||
Levodopa-carbidopa intestinal gel (Duodopa®) is recommended as an option for restricted use within NHS Wales. Levodopa-carbidopa intestinal gel (Duodopa®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results:
Levodopa-carbidopa intestinal gel (Duodopa®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | levodopa-carbidopa intestinal gel (Duodopa®) | ||
| Formulation | 20 mg/ml and 5 mg/ml intestinal gel | ||
| Reference number | 3397 | ||
| Indication | Treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results and patients are not eligible for deep brain stimulation |
||
| Company | AbbVie Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Resubmission | ||
| Status | Recommended with restrictions | ||
| Advice number | 0518 | ||
| NMG meeting date | 04/10/2017 | ||
| AWMSG meeting date | 14/03/2018 | ||
| Date of issue | 22/03/2018 | ||
| Date of last review | March 2021 | ||
| Commercial arrangement | WPAS | ||